Emcure Pharmaceuticals IPO Allotment Status Online: Emcure Pharmaceuticals IPO is Open on 3 July, 2024 and Close on 5 July, 2024. Emcure Pharmaceuticals IPO to Raise 19,365,346 shares (Approx ₹1,952.03 Cr) via IPO. The Fresh Issue of 7,936,507 shares (Approx ₹800.00 Cr) and The Offer For Sale Is 11,428,839 shares of ₹10 (Approx ₹1,152.03 Cr).
- The Retail Quota is 35%
- QIB is 50%
- NII is 15%
Emcure Pharmaceuticals IPO Basis of Allotment Status on 8 July, 2024. Emcure Pharmaceuticals IPO Refund Date is 9 July 2024 and Emcure Pharmaceuticals IPO Credit to Demat on 9 July 2024.
Also Read: Emcure Pharmaceuticals IPO details, Date, Price, GMP, Review,
Emcure Pharmaceuticals IPO Allotment Link Online
Linktime
Linktime Allotment Link
Moneymintidea
IPO Allotment Status Link
About –
Emcure Pharmaceuticals are one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
We are a research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled us to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada.
We were ranked as Company :-
(i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT September 2023.
(ii) the 4th largest pharmaceutical company by market share in our Covered Markets in terms of Domestic Sales for MAT September 2023.
(iii) the largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT September 2023.
Our competitive advantage in the domesti market stems from our differentiated product portfolio, which has allowed us to establish our presence in most of the major therapeutic areas, including gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/anti-neoplastics.
We are focused towards pharmaceutical products used in chronic (including sub-chronic) therapeutic areas. We have 13 manufacturing facilities across the states of Maharashtra, Gujarat, Sikkim and Karnataka and the union territory of Jammu and Kashmir, in India.
Our facilities are capable of producing pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. Further, our ability to manufacture our own APIs and formulations has allowed us to attain a significant degree of vertical integration, allowing us to source products in a cost-effective manner, ensure quality and security of availability of an essential raw material and protect our intellectual property. In particular, we have in-house manufacturing capabilities for most of our specialty products, including
complex injectables, iron products, photo-chemistry products, chiral molecules and biotherapeutics.
